Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity
C. Grandjacques et al., Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity, J HEPATOL, 33(3), 2000, pp. 430-439
Backguound/Aim: We aimed to clarify the clinical relevance of hepatitis B v
irus pre-core mutant detection in patients with chronic hepatitis B using a
newly developed assay.
Methods: Viral genotypes and pre-core mutations were studied in relation to
viral persistence and liver disease severity using INNO-LiPA methodology.
The study group included 151 patients with chronic hepatitis B, 85 positive
for HBeAg (group I) and 66 positive for anti-HBe (group LT).
Results: The prevalence of viral genotypes in group I was: 64% A, 1% B, 15%
C, 19% D, 0% E, 0% F and in group II: 39% A, 0% B, 2% C, 56% D, 2% E, 2% F
(p<0.001). The prevalence of mutations at pre-core codon 28 (M2) was lower
in group I (5%) than in group II (64%) (p<0.001). The prevalence of pre-co
re promoter mutations was also lower in group I (21%) than in group II (61%
) (p <0.001). M2 mutations were more frequently detected in genotype D than
in genotype A (p<0.001), while the other mutations were not influenced by
viral genotype. Serum HBV DNA levels were significantly lower in group II v
el sus group I (p<0.001), and in patients with any of the pre-core mutation
s versus wild-type sequence (p<0.01). Although cirrhosis was more frequent
in group II (37%) versus group I (22%) and in patients with either one of t
he pre-core mutation (31%) versus wild-type sequence (25%), there was no st
atistical difference in liver severity assessed by ALT levels and Knodell s
core.
Conclusion: Pre-core mutants, whose molecular pattern is strongly dependent
on viral genotypes, are associated with viral persistence in anti-HBe posi
tive patients with ongoing chronic hepatitis 13. The availability of this r
apid assay should allow a precise monitoring of viral pre-core mutants duri
ng the course of chronic hepatitis B.